Showing results (1611-1620 of 2,182) with videos related to
Sort By:
Pageof 219
Journal of Biopharmaceutical Statistics|July 27, 2026
Balancing sample size and accuracy of dose selection in phase 1 oncology trials - designs tiered by cohort size and maximum number of patients treated per dosePing Gao, Xun Zhang, Weidong Zhang, et al.Journal of Biopharmaceutical Statistics|July 31, 2026
A phase II, seamless single-arm to two-arm Bayesian design for a time-to-event endpointYun Qing, Ruitao LinJournal of Biopharmaceutical Statistics|August 11, 2026
An integrated methodological roadmap for real-world biomarker studies: advancing oncology precision medicine through robust methodologies and machine learning integrationDai Feng, Amber Lind, Weili HeJournal of Biopharmaceutical Statistics|September 29, 2026
Model generalizability considerations in development and evaluation of SaMDNing Leng, Yichen Lu, Jane Fridlyand, et al.Journal of Biopharmaceutical Statistics|October 15, 2026
Adaptation of Bayesian decision analysis for clinical trial design to binary outcomes: illustration for Ebola virus disease treatmentDrifa Belhadi, Joonhyuk Cho, Pauline Manchon, et al.Journal of Biopharmaceutical Statistics|October 23, 2026
ANPP: The adapted normalized power prior for borrowing information from multiple historical datasets in clinical trialsYueqi Shen, Matthew A Psioda, Luiz M Carvalho, et al.Journal of Biopharmaceutical Statistics|October 29, 2026
Estimand-based design strategies for cardiovascular recurrent event trials of combination therapiesAyon MukherjeeJournal of Biopharmaceutical Statistics|June 10, 2025
Approximate Bayesian estimation of time to clinical benefit using Frequentist approaches: an application to an intensive blood pressure control trialFang Shao, Guoshuai Shi, Zhe Lv, et al.Journal of Biopharmaceutical Statistics|December 12, 2022
Addressing statistical issues when leveraging external control data in pediatric clinical trials using Bayesian dynamic borrowingEmmanouil Spanakis, Martina Kron, Mareike Bereswill, et al.Journal of Biopharmaceutical Statistics|July 6, 2022
Optimal designs for phase II clinical trials with heterogeneous patient populationsLu Liu, Shiwei Cao, Sin-Ho JungPageof 219